Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Persistent or Recurrent Cervical Squamous Cell Carcinoma
NCT00031993Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2002
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in cervical squamous cell carcinoma (CSCC), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival at 6 months and Frequency and Severity of Adverse Effects up to 5 years. Started Mar 2002; status: completed.
02
Drugs
erlotinib
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT00031993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031993.